Hazel Therapeutics

Localized RNA therapeutics for osteoarthritis

Hazel Therapeutics is a biotechnology spin-out from the Technical University of Denmark (DTU) developing RNA medicines designed to halt the molecular drivers of osteoarthritis. Our approach combines antisense oligonucleotides with a proprietary sustained-release biomaterial to enable long-term gene silencing directly within the joint

More than 500 million people live with osteoarthritis

A growing global health burden

Osteoarthritis affects more than 500 million people worldwide and is one of the leading causes of pain, disability, and loss of mobility. As populations age, the number of patients continues to rise, placing a growing burden on healthcare systems and societies.Current therapies primarily treat symptoms such as pain and inflammation. However, the underlying biological processes driving cartilage degeneration continue to progress.

It’s time to deliver disease-modifying therapies

A new generation of long-acting, injectable RNA medicines

Precision RNA delivery directly to the joint

Hazel Therapeutics develops locally injected RNA medicines designed to address the molecular drivers of osteoarthritis. Our therapies silence key genes involved in inflammation and cartilage degradation directly within the joint.Using our proprietary sustained-release biomaterial technology, therapeutic RNA molecules remain active in the joint for extended periods, enabling long-lasting biological effects from a single injection.

Built by scientists and clinicians

Hazel Therapeutics was founded by scientists and clinicians with deep expertise in RNA therapeutics, biomaterials, and osteoarthritis biology. Our team combines translational research, drug delivery engineering, and clinical insight to develop the next generation of locally delivered RNA medicines